Progyny (PGNY) reported $1.3B in revenue for fiscal 2025, +10.4% year on year. That ranks #1616 by revenue among 2853 SEC filers and #149 in Healthcare. Net income was $58.5M, a net margin of 4.5%. Revenue has grown 50.6% a year on average since 2017 ($48.6M then). The fiscal 2025 balance sheet shows $742M in total assets and $112M in cash.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $1.3B | +10.4% | FY20252025-12-31 |
| Gross profitGrossProfit | $304M | +20.2% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $85.3M | +26.4% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $58.5M | +7.7% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $210M | +17.4% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $18.4M | +240.6% | FY20252025-12-31 |
| Total assetsAssets | $742M | +22.3% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $516M | +22.3% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $112M | −30.9% | FY20252025-12-31 |
| Long-term debt | Not reported | — |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $329M | $24.2M | Open → |
| Q2 20262026-06-30 | $351M | $28.1M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 89 of 161 companies compared | 4.5% | |
| Operating marginRank 101 of 160 companies compared | 6.6% | |
| R&D as share of revenueRank 95 of 102 companies compared | 0.7% | |
| Cash as share of revenueRank 100 of 160 companies compared | 8.7% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Progyny, Inc.
- Ticker
- PGNY
- Exchange
- Nasdaq
- SIC classification
- Services-Misc Health & Allied Services, NEC (8090)
- Fiscal year end
- 12-31
- CIK
- 0001551306
Filings
- 10-QAug 7, 2026Open filing →
- 10-QMay 8, 2026Open filing →
- 10-KFeb 27, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Stevanato GroupSTVN | $1.3B | $158M |
| HaemoneticsHAE | $1.3B | $97,308 |
| Phibro Animal HealthPAHC | $1.3B | $48.3M |
| ProgynyPGNY | $1.3B | $58.5M |
| Curaleaf HoldingsCURLF | $1.3B | −$231M |
| Lakefront BiotherapeuticsLKFT | $1.3B | $363M |
| Indivior PharmaceuticalsINDV | $1.2B | $210M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Progyny — Key figures |url=https://companiesranked.com/en/company/progyny |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Progyny — Key figures. CompaniesRanked. https://companiesranked.com/en/company/progynyBibTeX
@misc{companiesranked-en-company-progyny-2026,
author = {{CompaniesRanked}},
title = {{Progyny — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/progyny}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001551306-26-000020 · February 27, 2026
{{cite web |title=Progyny — Key figures — 10-K (0001551306-26-000020) |url=https://www.sec.gov/Archives/edgar/data/1551306/000155130626000020/pgny-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-27}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.